

Edgar Filing: CERUS CORP - Form SC 13D/A

CERUS CORP
Form SC 13D/A
July 03, 2001

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No. 3) *

CERUS CORPORATION

(Name of Issuer)

COMMON SHARES \$0.001 PAR VALUE PER SHARE

(Title of Class of Securities)

157085 10 1

(CUSIP Number)

Jan Stern Reed
BAXTER INTERNATIONAL INC.
One Baxter Parkway
Deerfield, Illinois 60015
847.948.2212

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

June 29, 2001

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this Schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box.

NOTE: Schedules filed in paper format should include a signed original and five (5) copies of the schedule. See Rule 13d-7(b) for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act

Edgar Filing: CERUS CORP - Form SC 13D/A

but shall be subject to all other provisions of the Act (however, see the Notes).

(Continued on following page(s))

CUSIP No. 157085 10 1

NAMES OF REPORTING PERSONS

1 S.S or I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only).

BAXTER INTERNATIONAL INC. ("Parent")
I.R.S Identification Number: 36-0781620

BAXTER HEALTHCARE CORPORATION ("Holder")
I.R.S Identification Number: 36-2604143

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

2 (a)
(b)

SEC USE ONLY

3

SOURCE OF FUNDS (See Instruction)

4 N/A

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 3(e)

5

CITIZENSHIP OR PLACE OF ORGANIZATION

6 Delaware

SOLE VOTING POWER

7
NUMBER OF
SHARES

-0-

BENEFICIALLY

8

SHARED VOTING POWER

OWNED BY

270,337

EACH
REPORTING

9

SOLE DISPOSITIVE POWER

-0-

PERSON

WITH

10

SHARED DISPOSITIVE POWER

270,337

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

11 270,337

Edgar Filing: CERUS CORP - Form SC 13D/A

12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(See Instructions) []

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
1.7%

14 TYPE OF REPORTING PERSON (See Instructions)
CO

Page 2 of 6 Pages

CUSIP No. 157085 10 1

This Amendment No. 3 to Schedule 13D (the "Amendment") relates to the holdings of Baxter Healthcare Corporation, a Delaware corporation ("Holder") of common stock, \$0.001 par value per share ("Common Stock") of Cerus Corporation, a Delaware corporation (the "Company"). The Amendment amends and supplements the previously filed Schedule 13D, as amended, as follows:

Item 4. PURPOSE OF TRANSACTION. The following is hereby added to the end of Item 4.

Holder disposed of 1,800,000 shares of Common Stock on June 29, 2001.

Holder contributed, in a private placement, 1,800,000 shares of Common Stock to the Baxter International Inc. and Subsidiaries Pension Trust, effective June 29, 2001, at the closing price of the Company's Common Stock per share, on June 28, 2001, as reported in the NASDAQ national market quotation service.

In addition, Section 4.2 of the Red Cell Agreement has been amended as set forth in Exhibit 7.4, which Exhibit is incorporated herein by reference.

Accounting Treatment

The accounting gain from this disposition of Common Stock will be substantially offset by impairment charges for non-strategic investments and assets of Holder or Parent.

Item 5. INTEREST IN SECURITIES OF THE ISSUER:

Except as set forth herein, neither Holder, or Baxter International Inc., a Delaware corporation (the "Parent"), nor, to the best of the knowledge of Holder and Parent, any director or executive officer of Holder or Parent beneficially owns any other shares of Common Stock of the Company.

(a) As of July 2, 2001, Holder and Parent beneficially owned an aggregate of 270,337 shares of Common Stock, which constitute approximately 1.7% of the total number of presently outstanding shares of Common Stock. No further reports will be made on behalf of Holder or Parent.

(b) Holder and Parent share the power to vote and dispose of the

Edgar Filing: CERUS CORP - Form SC 13D/A

Common Stock.

(c) Not Applicable.

(d) Not Applicable.

(e) Not Applicable.

Item 6. CONTRACTS OR ARRANGEMENTS WITH RESPECT TO ISSUER SECURITIES.

The disclosure in Item 6 is amended to add this sentence at the end of the final paragraph of this Section.

Section 4.2 of the Red Cell Agreement has been amended as set forth in Exhibit 7.4, which Exhibit is incorporated herein by reference.

Page 3 of 6 Pages

Item 7. MATERIALS TO BE FILED AS EXHIBITS.

Exhibit 7.4 Letter, dated June 28, 2001, amending Section 4.2 of that certain Development, Manufacturing and Marketing Agreement, effective as of April 1, 1996, and amended and restated effective as of June 30, 1998 by and between Baxter Healthcare Corporation and Cerus Corporation.

Page 4 of 6 Pages

S I G N A T U R E

After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned corporations certifies that the information set forth in this Statement is true, complete and correct.

Dated: July 2, 2001

BAXTER HEALTHCARE CORPORATION

By: /S/Jan Stern Reed

Corporate Secretary

BAXTER INTERNATIONAL INC.

By: /S/Jan Stern Reed

Corporate Secretary

Page 5 of 6 Pages